Table 4.
List of studies investigating the performances of ImmunoCyt test in surveillance setting in non-muscle invasive bladder cancer patients
| Author (year) reference | Study design | No. of patients | Sensitivity (%) | Specificity (%) | Other end points |
|---|---|---|---|---|---|
| Vriesema (2001) [94] | Cohort | 86 | 50 | 73 | PPV 39%, NPV 81% |
| Pfister (2003) [95] | Cohort | 458 | 70 | 82 | – |
| Tetu (2005) [96] | Cohort | 904 | 74 | 62 | PPV 26%, NPV 93% |
| Messing (2005) [97] | Cohort | 341 | 81 | 75 | – |
| Lodde (2006) [98] | Cohort | 195 | 84 | 86 | PPV 63%, NPV 92% |
| Mian (2006) [27] | Marker-guided prospective | 942 | 85 | 72 | – |
| Sullivan (2009) [99] | Cohort | 100 | 76 | 63 | PPV 43%, NPV 88% |
| Horstmann (2009) [85] | Cohort | 221 | 73 | 62 | PPV 72%, NPV 74% |
| Yafi (2015) [17] | Marker-comparison prospective | 109 | 62 | 79 | – |
| Bell (2016) [18] | Marker-comparison prospective | 91 | – | – | No association with RFS or PFS |
PPV positive predictive value, NPV negative predictive value, RFS recurrence-free survival, PFS progression-free survival